New combo therapy for tough lung cancer tested in early trial
NCT ID NCT05403723
First seen Feb 22, 2026 · Last updated May 20, 2026 · Updated 15 times
Summary
This early-stage trial is testing whether adding a special type of radiation (adaptive SBRT) to standard immunotherapy and chemotherapy is safe for people with advanced small cell lung cancer that has stopped responding to platinum chemo. About 50 adults with this cancer will receive the combination. The main goal is to see how many patients have side effects, and researchers will also check if tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.